🇺🇸 FDA
Patent

US 12269886

Tetravalent bispecific antibody against PD-1 and PD-L1

granted A61KA61K2039/505A61K2039/545

Quick answer

US patent 12269886 (Tetravalent bispecific antibody against PD-1 and PD-L1) held by SUNSHINE GUOJIAN PHARMACEUTICAL (SHANGHAI) CO., LTD. expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
SUNSHINE GUOJIAN PHARMACEUTICAL (SHANGHAI) CO., LTD.
Grant date
Tue Apr 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
10
CPC classes
A61K, A61K2039/505, A61K2039/545, A61P, A61P35/00